Vimta Labs Q1 FY26‑27: Strong Growth, New Biologics Launch & Robust Outlook
Vimta Labs Q1 FY 2026‑27 shows resilient growth across pharma, clinical, and testing services, with a new biologics facility securing its first order.
3 minutes to read
EUROFINS SCIENTIFIC
Eurofins Surpasses Half‑Year Targets, Boosts Growth With $400M Life Sciences Acquisition
Eurofins Scientific beats Q1 earnings expectations, drives €3.12 bn revenue growth with strategic acquisitions and a focus on biopharma testing.
2 minutes to read
Eurofins Boosts Share Value & U.S. Presence with $400 M Testing Acquisition
Eurofins Scientific SE balances growth and value: shares rise, a €6.9 M buyback boosts EPS, and a $400 M acquisition of EMT expands its North American life‑sciences testing reach.
5 minutes to read
Eurofins Shares Buyback Signals Confidence & Drives Strategic Growth Plans
Eurofins Scientific’s June share‑repurchase signals confidence, boosts shareholder value and underlines its strategy to grow in personalized medicine and global bio‑analysis markets.
4 minutes to read